Benzinga | Jan 10, 2022 04:27PM EST

Illumina Reports Companion Diagnostic Partnership With Boehringer Ingelheim, No Terms Disclosed

Illumina Inc. (NASDAQ:ILMN) today announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) for several programs in Boehringer Ingelheim's oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.



The partnership spans current and future CDx programs, with plans to add CDx claims to an in vitro diagnostic test Illumina is developing that is based on the content of TruSight(tm) Oncology 500 (TSO 500). The first program will co-develop a CDx for a Boehringer Ingelheim investigational medicine.

"We are delighted that Boehringer Ingelheim has chosen Illumina to be its long-term partner in the development of companion diagnostics for the treatment of cancers," said Joydeep Goswami, Chief Strategy and Corporate Development Officer of Illumina. "Illumina continues to provide the leading distributable assay enabling comprehensive genomic profiling for both tissue and liquid biopsy and together we will unlock the potential of new biomarkers to identify patients most likely to benefit from new precision medicines."